Printer Friendly

Studies Support the Use of the CyberKnife System as a Safe and Effective Option to Treat Neurological Diseases.

-- Five Year Follow-up Studies Demonstrate Excellent Results for Perioptic Meningiomas

SUNNYVALE, California, Nov. 3, 2014 /PRNewswire/ -- Accuray Incorporated (Nasdaq: ARAY) announced that studies presented at the 15[sup.th] European Congress of Neurosurgical Societies (EANS) in Prague, October 12 C 17, 2014 reinforce the benefits of the CyberKnife Robotic Radiosurgery System for the treatment of neurological diseases such as meningiomas, acoustic neuromas, trigeminal neuralgia, and spinal tumors.

Dr. Alfredo Conti, neurosurgeon at the University Hospital of Messina in Italy is using the CyberKnife System to treat perioptic meningiomas. The flexibility of the CyberKnife System enabled by its unique architecture allows tumor control while preserving vision. The results he presented in a plenary session included a series of 64 patients with perioptic meningiomas treated in 2-5 fractions with CyberKnife schemes between July 2007 - May 2010[sup.[i]].

The study included two cohorts of patients with different tumor volumes. In one cohort, 25 patients with a small tumor volume (less than 5 cc) were followed for an average of 60 months (+12 months). In the second cohort, 39 patients with a larger tumor volume (7.5 cc) were followed for an average of 17 months (+10 months). No visual deterioration was observed and tumor control was achieved in all cases.

These results support the clinical benefits of CyberKnife treatment for perioptic meningiomas, and were achieved thanks to the ability to fractionate depending on the tumor volume and its proximity to the optic nerve.

"The CyberKnife Robotic Radiosurgery System is able to treat safely and efficiently tumors with large volumes, in particular meningiomas, as well as acoustic neuromas," says Dr. Alfredo Conti. "This is a real breakthrough because treating large tumors with radiosurgery in a single fraction is very challenging, and often not possible. Furthermore, treating tumors close to the optic nerves or other critical brain structures is sometimes very challenging for neurosurgeons and the CyberKnife System represents a safer and effective treatment option."

A second study done by Prof. Pantaleo Romanelli, CyberKnife Center, Centro Diagnostico Italiano, Milano, Italy evaluated the clinical benefits of the CyberKnife System as a treatment for patients with trigeminal neuralgia (TN) [ii]. A cohort of 103 patients was treated with a 60 Gy dose delivered in a single fraction by the CyberKnife System.

Results indicate that use of the CyberKnife System provides a safe and effective treatment option for people with TN. After six months, more than 90 percent of patients showed significant improvement in their symptoms. The system also provided an opportunity to successfully retreat 24 patients who had relapsed within two years from their first treatment.

Finally, at the Accuray symposium held in Prague at the 15th EANS congress, Prof. Alexander Muacevic, director of the Europaisches CyberKnife Zentrum in Munich, Germany, presented the extension of indications, such as spinal tumors, treated with the CyberKnife System. "The CyberKnife Robotic Radiosurgery System is safe and effective in the treatment of spinal lesions. It treats with a sub millimeter accuracy, which is crucial for tumor treatments all along the spine," says Prof. Alexander Muacevic.

Further information on this system is available at http://www.accuray.com/solutions/treatment-delivery/cyberknife-treatment-delivery/m6-series

Disclaimer: Side effects of CyberKnife and TomoTherapy treatment are usually mild and temporary, may include nausea, fatigue and skin irritation, and may vary from patient to patient. As with any radiation treatment, the side effects can also be severe in some patients and lead to permanent injury or even death, and results may vary from patient to patient.

About the CyberKnife System The Accuray CyberKnife M6 Series enables precise, high-quality, dose distributions to be confidently delivered to the patient with extreme accuracy over a minimum number of treatments, reducing side effects and preserving patients' quality of life. The CyberKnife System is the only robotic full-body radiosurgery system available today.

About Accuray Accuray Incorporated (Nasdaq: ARAY) is a radiation oncology company that develops, manufactures and sells precise, innovative tumor treatment solutions that set the standard of care with the aim of helping patients live longer, better lives. The company's leading-edge technologies deliver the full range of radiation therapy and radiosurgery treatments. For more information, please visit www.accuray.com.

Safe Harbor Statement Statements made in this press release that are not statements of historical fact are forward-looking statements and are subject to the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements in this press release relate, but are not limited, to clinical experience, applications, performance and results, patient treatment outcomes, and Accuray's leadership position in radiation oncology innovation and technologies. Forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially from expectations, including but not limited to the risks detailed under the heading "Risk Factors" in the company's report on Form 10-K, filed on August 29, 2014, and the company's other filings with the SEC.

Forward-looking statements speak only as of the date the statements are made and are based on information available to the company at the time those statements are made and/or management's good faith belief as of that time with respect to future events. The company assumes no obligation to update forward-looking statements to reflect actual performance or results, changes in assumptions or changes in other factors affecting forward-looking information, except to the extent required by applicable securities laws. Accordingly, investors should not put undue reliance on any forward-looking statements.

Abstracts[i] HYPOFRACTIONATED STEREOTACTIC RADIOTHERAPY FOR PERIOPTIC MENINGIOMAS. INTERMEDIATE-TERM RESULTS AND RADIOBIOLOGICAL CONSIDERATIONS A. Conti[sup.1], A. Pontoriero[sup.2], G. IatE1/4[sup.2], A. Brogna[sup.3], C. Siragusa[sup.3], D. La Torre[sup.1], C. Tomasello[sup.4], S. Pergolizzi[sup.1], C. De Renzis[sup.2], F. Tomasello[sup.1]. [sup.1]Neurosurgery, University of Messina, Messina, Italy. [sup.2]Radiation Oncology, University of Messina, Messina, Italy. [sup.3]Medical Physiscs, University of Messina, Messina, Italy. [sup.4]Oncology, University of Messina, Messina, Italy 15[sup.th] European Congress of Neurosurgical Societies (EANS) in Prague, October 12 C 17, 2014

[ii] CYBERKNIFE RADIOSURGERY FOR TRIGEMINAL NEURALGIA P. Romanelli[sup.1], G. Beltramo[sup.1], L. Bianchi[sup.1]. [sup.1]Cyberknife Center, Centro Diagnostico Italiano, Milano, Italy. 15[sup.th] European Congress of Neurosurgical Societies (EANS) in Prague, October 12 C 17, 2014

RELATED LINKS http://www.accuray.com
COPYRIGHT 2014 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2014 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire Europe
Geographic Code:4EXCZ
Date:Nov 3, 2014
Words:1206
Previous Article:Globecomm and Gannexion Expand Their E-Welfare Platform for Government Operations in the EMEA Region.
Next Article:Royal London selects Milliman for Actuarial Systems Transformation.
Topics:

Terms of use | Copyright © 2018 Farlex, Inc. | Feedback | For webmasters